Huan Dong

Tianjin, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Journal: Haematologica

Published: June 01, 2026

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia.

Journal: British journal of haematology

Published: April 16, 2026

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Clinical heterogeneity in congenital factor XII deficiency: Coexisting risk factors in thrombotic and bleeding events.

Journal: British journal of haematology

Published: February 24, 2026

Crop gene regulatory networks for precision breeding in saline environments.

Crop gene regulatory networks for precision breeding in saline environments.

Journal: Plant physiology and biochemistry : PPB

Published: December 19, 2025

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial.

Journal: Annals of hematology

Published: November 25, 2025

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Journal: EClinicalMedicine

Published: November 05, 2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Journal: BMJ (Clinical research ed.)

Published: October 21, 2025

The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.

The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping.

Journal: Hematology (Amsterdam, Netherlands)

Published: October 06, 2025

Combined mesenchymal stem cells and telitacicept therapy for Evans syndrome refractory to various immunosuppressive: a case report.

Combined mesenchymal stem cells and telitacicept therapy for Evans syndrome refractory to various immunosuppressive: a case report.

Journal: Research and practice in thrombosis and haemostasis

Published: August 25, 2025

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: August 25, 2025

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 24, 2025

The influencing factors of multiple disease burdens among middle-aged and elderly people in China.

The influencing factors of multiple disease burdens among middle-aged and elderly people in China.

Journal: Medicine

Published: December 19, 2024

Showing 1-12 of 39

Last Updated: 09/26/2026